Skip to main content
. 2020 Jul 27;146(10):2575–2587. doi: 10.1007/s00432-020-03315-6

Fig. 2.

Fig. 2

Summary of grade 3, 4, and 5 adverse events occurring in > 2% of patients in two or more studies